RT Journal Article SR Electronic T1 Compound could help diabetic patients walk tightrope between heperglycemia, hypoglycemia JF Canadian Medical Association Journal JO CMAJ FD Canadian Medical Association SP 705 OP 707 VO 154 IS 5 A1 F. Lowry YR 1996 UL http://www.cmaj.ca/content/154/5/705.abstract AB A pharmaceutical company is proceeding with clinical testing of a new compound that could make it easier for diabetic patients to maintain good control of blood-sugar levels. The compound, a peptide called amylin, appears to lessen wild fluctuations in blood-glucose levels by slowing the rate of gastric emptying and moderating the amount of postprandial glucose. Fran Lowry interviewed the researcher who discovered the peptide.